-+ 0.00%
-+ 0.00%
-+ 0.00%

Yifan Pharmaceutical announced that its wholly-owned subsidiary Yifan Pharmaceutical signed an “Exclusive Agreement” with Suntech Pharmaceutical to obtain exclusive rights to ACT001. Yifan Pharmaceutical is required to pay 100 million yuan in payments from the head of state, 100 million yuan in cornerstone investment funds, or 50 million yuan in milestone payments, and the distribution is based on net sales.

Zhitongcaijing·01/05/2026 09:41:04
Listen to the news
Yifan Pharmaceutical announced that its wholly-owned subsidiary Yifan Pharmaceutical signed an “Exclusive Agreement” with Suntech Pharmaceutical to obtain exclusive rights to ACT001. Yifan Pharmaceutical is required to pay 100 million yuan in payments from the head of state, 100 million yuan in cornerstone investment funds, or 50 million yuan in milestone payments, and the distribution is based on net sales.